The priorities for antiviral drug resistance surveillance and research

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue SUPPL. 1, 2007, Pages

  Pillay, Deenan ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Hepatitis C; Herpes; HIV; Influenza; Transmission

Indexed keywords

ANTIVIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; HEALTH SURVEY; HUMAN; INFECTION CONTROL; METHODOLOGY; VIRUS INFECTION;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, VIRAL; HUMANS; POPULATION SURVEILLANCE; VIRUS DISEASES;

EID: 34948901448     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm159     Document Type: Article

References (13)

1. Crotty S, Cameron SE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001; 98: 6895-900.
2. Ghani A, de Wolf F, Ferguson N et al. Surrogate markers for disease progression in treated HIV infection. J Acquir Immune Defic Syndr 2001; 28: 226-31.
3. Gubavera LV, Kaiser L, Hayden F. Influenza virus neuraminidase inhibitors. Lancet 2000; 355: 827-3.
4. Colizza V, Barrat A, Barthelemy M et al. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PLoS Med 2007; 4: e13.
5. White KL, Margot NA, Ly JK et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005; 19: 1751-60.
6. Rhee SY, Taylor J, Wadhera G et al. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci USA 2006; 103: 17355-60.
7. Nijhuis M, van Maarseveen NM, Lastere S et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4: e36.
8. Grover D, Allen L, Edwards SG et al. Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK. Antiviral Therapy 2005; 10: S7.
9. Cane P, Chrystie I, Dunn D et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331: 1368.
10. Gazzard B, Bernard AJ, Boffito M et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7: 487-503.
11. Reesink HW, Zeuzem S, Weegink CJ. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebocontrolled, randomized study. Gastroenterology 2006; 131: 997-1002.
12. Le Pogem S, Kang H, Harris SF et al. Selection and characterization of replicon variants dually resistant to thumb-and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006; 80: 6146-54.
13. The Royal Society and the Academy of Medical Sciences 2006. Pandemic Influenza: Science to Policy. http://www.royalsoc.ac.uk/displaypagedoc.asp?id=22903 (4 April 2007, date last accessed).